Background: The ACCORD 16 phase II trial aimed to evaluate the objective response rate after combination of conventional chemoradiotherapy (CRT) and cetuximab in locally advanced anal canal carcinoma (LAACC).
Patients and methods: Immunocompetent patients with histologically confirmed LAACC received CRT [45 gray (Gy)]
in 25 fractions over 5 weeks, fluorouracil and cisplatin during weeks 1 and 5), in combination with weekly dose of cetuximab (250 mg/m 2 with a loading dose of 400 mg/m 2 1 week before irradiation), and a standard dose boost (20 Gy).
The trial was originally designed to include 81 patients to detect a 15% of objective response increase with the new combination in comparison with CRT.
Results:
The trial was prematurely stopped after the declaration of 15 serious adverse events (SAEs) in 14 out of 16 patients. Five patients received the entire planned treatment, and the compliance was higher after amendments of the protocol. Among the 15 SAEs, 6 were unexpected. Grade (G) 3/4 acute toxic effects, observed in 88% patients, were general (n = 13, 81%), digestive (n = 9, 56%), dermatological (n = 5, 31%), infectious (n = 4, 25%), haematological (n = 3, 19%), and others (n = 9); and three patients suffered from six G3/4 late toxic effects. No treatment-related death was reported. All 11 assessable patients had an objective response consisting of six complete (55%) and five partial (45%) response 2 months after the end of the treatment. Thirteen patients were followed up with a median of 22 months [95% confidence interval (CI ): 18-27] and had a 1-year colostomy-free survival, progression-free and overall survival rate of 67% (95% CI: 40%-86%), 62% (95% CI: 36%-82%), and 92% (95% CI: 67%-99%), respectively.
Conclusion: CRT plus cetuximab was unacceptably toxic in this population of patients. Results of others phase II trials evaluating this combination are awaited to confirm these findings. [1] [2] [3] . However, a lower survival and higher local failure rates (25% at 2 years) are reported in patients with advanced tumours (i.e. stage T3-T4 and or positive nodes) [4] . Induction chemotherapy was evaluated in a phase II study of the cancer and Leukemia Group B (CALGB 9281) in 45 patients with locally advanced anal canal carcinoma (LAACC) and resulted in a colostomy-and disease-free rate of 50% [5] . Despite these encouraging results, in the randomized ACCORD 03 trial, intensified CRT with the addition of induction chemotherapy and/or an additional radiation boost failed to increase the colostomy-free survival in comparison with standard CRT [6] .
Preclinical evidence suggests that cetuximab, an IgG1 monoclonal antibody that exclusively targets epidermal growth factor receptor (EGFR) with high affinity, has radiosensitizing properties [7] . In patients with locally advanced head and neck cancer, CRT with cetuximab improved LC and OS in comparison with RT alone [8] . Since then, recent phase II studies have shown that addition of cetuximab to platinumbased CRT is feasible, and show promising activity without increasing mortality in various advanced tumour types [9] [10] [11] [12] . EGFR expression is common in anal cancer [13] . In preliminary results of a phase I trial evaluating 10 patients with LAACC, the combination of RT [45 gray (Gy) plus a boost of 20 Gy], cetuximab (400 mg/m 2 on day 1, then seven weekly doses of 250 mg/m 2 ), and a dose escalation of 5-fluorouracil (5-FU) and cisplatin resulted in one grade (G) 4 toxicity (neutropenic fever) only [14] . In the light of these emerging data, the ACCORD 16 phase II trial aimed to evaluate the objective response rate after conventional CRT combined with cetuximab in LAACC patients.
patients and methods

eligibility criteria
Eligible patients had histologically confirmed locally advanced [T2 (tumour size >3 cm) to T4 and/or N1-N3] anal squamous cell cancer with measurable disease according to the RECIST criteria. Initial imaging evaluation included an endorectal ultrasonography and a body computed tomography (CT).
All patients were human immunodeficiency virus (HIV)-negative, had World Health Organization performance status of 0 to 2, with no metastatic disease. Other inclusion criteria were age ≥18 years, adequate bone marrow, renal and liver function, and a negative pregnancy test. Written informed consent was obtained from each patient before study entry. Patients with other histological subtype or a past medical history including another cancer, previous cancer treatment, or HIV-positive were excluded from the study. The protocol was approved by the Kremlin-Bicetre ethics committee.
treatment
Patients received external-beam conformal RT (EBRT) or intensity modulated RT (IMRT) at a total dose of 45 Gy in the pelvis, calculated at the International Commission of Radiation Units reference point, at the intersection of the central axes of the beams, in daily fractions of 1.8 Gy, according to EORTC [3] and UKCCCR trials [1] . All fields were treated every day, 5 days per week for a total of 5 weeks. Briefly, IMRT plans were generated using the commercial inverse planning software (Eclipse, Helios, version 7.2.34, Varian, Palo Alto, CA). Beam geometry consisted of seven coplanar fields for the whole pelvis, and a five-field technique was used for the IMRT boost. Patients were treated with an 18-MV linear accelerator with a millennium dynamic multileaf collimator (21EX, Varian, Palo Alto, CA).
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The same isocentre defined during the virtual simulation was used throughout the treatment. Typical input dose-volume starting constraints for planned target volume and organ at risk were previously described [15] . After a treatment break of 2 weeks at the end of the previous sequence, a boost limited to the anal canal and the macroscopic tumour was given by either EBRT or brachytherapy. This boost delivered a dose of 20 Gy, in daily fractions of 2 Gy daily, 5 days per week for a total of 2 weeks, achieving a total dose of 65 Gy on the anal canal and the macroscopic tumour. No concomitant chemotherapy was delivered during the boost (Supplementary Figure S1 , available at Annals of Oncology online).
Cetuximab was administered intravenously at a loading dose of 400 mg/m 2 1 week before RT, and then 250 mg/m 2 weekly during RT for a total of 6 weeks of treatment. Cisplatin and 5-FU were administered intravenously during the first and the fifth week of RT at a dose of 800 mg/m 2 daily during 3 days and 80 mg/m 2 daily during 1 day, respectively. Cisplatin and 5-FU were given 1 h after the administration of cetuximab and 2 h before RT.
dose modification and follow-up
Toxicity and adverse event assessments were carried out weekly according to the scale of Common Terminology Criteria for Adverse Events (CTC-AE) version 3.0. A serious adverse event (SAE) was defined as a clinically significant adverse event resulting in death, life-threatening, hospitalization or prolongation of hospitalization, or causing temporary or permanent severe disability. An unexpected SAE was defined as an event not listed or with different intensity than those described in the investigator's brochure. Late toxic effects were defined as toxic effects observed ≥3 months after inclusion. RT interruptions or delays were permitted for G3 diarrhoea, anitis, proctitis, and/or skin toxicity. Resumption of RT was allowed once toxicity had resolved to ≤G2. Chemotherapy was delayed for haematological toxicity until resolved to an absolute neutrophil count ≥1500/mm 3 and a platelet count ≥100 000/mm 3 . Dose reduction of cisplatin was allowed for digestive toxicity G3 or neurological toxicity ≥G2. Cetuximab-specific skin and hypersensitivity reactions were treated according to the prescribing information. G4 toxic effects or interruptions >2 weeks resulted in the removal of the patient from the protocol treatment. During the study treatment, patients were monitored by weekly clinical examination with full haematology, blood biochemistry, and liver function tests assessment. Overall response was evaluated during the 2-week treatment break ( physical examination) and 6 weeks after the completion of treatment by a CT scan and an endorectal ultrasound. All patients were followed up with clinical and biological examination every 3 months.
end points and statistical considerations
The main end point was to evaluate the objective response rate (defined as CR + partial response) of the combination of CRT and cetuximab 6 weeks after the end of the treatment, according to RECIST criteria (as determined by CT scan). The trial was originally designed to detect a 15% of objective response increase with the new combination based on a Simon design, and 81 patients were required for the study.
Secondary end points included toxic effects assessed by CTC-AE V3, LC, progression-free survival (PFS), OS, and the colostomy rate. PFS was measured from the date of registration to the date of disease progression, relapse, or death from any cause, and OS was calculated from the date of inclusion to the date of death from any cause or last visit. Patients without an event were censored at the last follow-up. The Kaplan-Meier method was used to estimate OS and PFS. 
trial conduct
A total of 16 patients with squamous LAACC were enrolled in the study. Supplementary Table S1, available at Annals of Oncology online, lists the main characteristics of the study population.
Between March and July 2009, 10 patients from six centres were included (first period of inclusion). In September 2009, inclusions were suspended after nine SAEs. Inclusions were resumed after protocol amendments [decreased the dose of 5-FU from 800 to 600 mg/m 2 /day in continuous infusion; secondary prophylaxis with granulocyte colony-stimulating factor (G-CSF); and mandatory IMRT with a reinforcement of IMRT constraints of the maximal dose allowed to the digestive tract] in January 2010, and six additional patients were enrolled in three centres (second period of inclusion). The inclusions were suspended and the trial was prematurely stopped after the declaration of six new SAEs in September 2010.
treatment delivery and compliance
The median dose delivered was 65 Gy (51.4-65) in 35 fractions (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) and 71 days (54-85) with either EBRT (n = 3) or IMRT (n = 11). A brachytherapy boost was administered in two patients. Owing to toxicity, RT was interrupted for a total of 14 days among three patients. Two patients received a total dose of <60 Gy. Data are missing for two patients who withdrew their consent after the first injection of cetuximab (Supplementary  Table S2 , available at Annals of Oncology online). Data on duration were missing in two other patients with early withdrawal.
Eight patients (50%) received the six planned injections of cetuximab. Three patients received the loading injection of cetuximab only and there were four definitive interruptions of treatment. No dose reduction of cetuximab was observed.
Three patients received 5-FU bolus (800 mg/m 2 ); and three and six patients received continuous 5-FU at a dose of 800 and 600 mg/m 2 /day, respectively. Two patients received continuous 800 mg/m 2 /day, as bolus for the first cycle and as continuous infusion for the second one. Two out of five patients (40%) receiving 5-FU bolus at the first cycle and one out of nine patients (11%) receiving continuous 5-FU at the first cycle did not receive the second cycle of 5-FU. Concerning cisplatin, three patients received only the first injection, two had a dose reduction during the second cycle, and one patient received 25% of the dose at each injection.
Overall, five patients received the entire planned treatment. The compliance was higher during the second period of inclusion: six patients received the entire planned treatment, except one dose reduction at the second cycle of cisplatin for one patient, and one non-toxicity-related dose reduction of RT.
toxicity Fifteen SAEs were observed in 14 out of 16 patients. One patients had two SAEs, and two SAEs were not related to the treatment. There were 6 unexpected SAEs out of 10 SAEs (60%) in the first period of inclusion and no unexpected SAE out of 5 SAEs (0%) in the second period of inclusion.
original articles Annals of Oncology G3/4 toxic effects were observed in 14 (88%) patients, and all patients but one had treatment-related toxicity. G3/4 acute toxic effects observed were general (n = 13), digestive (n = 9), dermatological (n = 5), infectious (n = 4), haematological (n = 3), and others (n = 9; Supplementary Table S3, available at Annals of Oncology online). No treatment-related death, G3/4 renal failure, or G3/4 anitis and proctitis was reported.
Three patients suffered from six severe late toxic effects. G3/4 late toxic effects observed were G3 abdominal (n = 1) and lumbar (n = 1) chronic pain, cutaneous (G3 acneiform eruption, n = 1), G3 mucositis (n = 1), G4 perineal necrosis (n = 1), G3 perineal fistula (n = 1), and G3 febrile syndrome (n = 1).
response and survival
All the 11 assessable patients had an objective response consisting of six complete (55%) and five partial (45%) response and one progression 2 months after the end of the treatment. Median objective response duration was 14.7 months (range: 2.5-24.4).
For the 13 patients with long-term follow-up, the median follow-up was 22 months [95% confidence interval (CI): 18-27]. Among these patients, five had a recurrence (38%), four local, and one distant, at a median time of 8 months (4.5-10). Five patients required a colostomy, due to local recurrence (n = 3) or fistulae (n = 2). Three patients died of their cancer during the follow-up. One-year colostomy-free survival, PFS, and OS rates were 67% (95% CI: 40%-86%), 62% (95% CI: 36%-82%), and 92% (95% CI: 67%-99%), respectively (Supplementary Figure S2 , available at Annals of Oncology online).
discussion
The UNICANCER ACCORD 16 phase II trial was prematurely stopped after the declaration of 15 SAEs in 14 out of 16 enrolled patients and a high rate of severe toxic effects (88%). Although the compliance being higher after amendments of the protocol (second period of inclusion), only five patients received the entire planned treatment.
In ACCORD 16, acute side-effects were higher than those previously described in the main randomized phase III trials reporting conventional CRT. In the CRT arms of the UKCCR [1] , the RTOG/ECOG [2] , and the ACCORD 03 [6] trials, acute side-effects were 34% (G3/4 or 'severe'; n = 100/292), 20% (G4/5), and 29% (G3/4; n = 46/157 without patients receiving induction CT but including patients with high-dose RT), respectively. Moreover, here, only 5 out of 16 (31%) patients received the entire planned treatment, whereas 74%-92% received the initially planned concomitant CT and 90%-98% completed RT in the previous studies [1, 2, 6] . Also, given the small size of the population, the short follow-up, and the poor compliance to the treatment, we agree that efficacy results may not be assessable in the present study.
Cetuximab combined with cisplatin/5-FU-CRT is currently evaluated in anal cancer patients in two other phase II trials: ECOG 3205 (immunocompetent) and AIDS Associated Malignancies Clinical Trials Consortium 045 (HIV-positive: AMC045). Patients generally received the same schedule of treatment that was delivered in our study, combining cetuximab (400 mg/m 2 loading, then 250 mg/m 2 /week for 6 to 8 weeks) plus cisplatin (75 mg/m 2 , two cycles) and 5-FU (1000 mg/m 2 /day infusion days 1-4, two cycles) concurrently with RT (45-54 Gy), beginning with the second dose of cetuximab. The patients also received two cycles of cisplatin/5-FU alone before CRT associated with cetuximab, but this was discontinued on the recommendation of the NCI Anorectal Task Force after a trial with 28 patients. The primary end point was the 3-year locoregional failure rate, and the early results on the first 28 patients from E3205 were presented at ASCO 2012 [16] . Severe toxic effects, defined as type I (any G4-5 G4 cardiac) and II (G4 RT skin or diarrhoea), were reported for two patients. This result was comparable with our experience (no G5, or G4 cardiac, skin, or diarrhoea in ACCORD 16) . No data was provided on haematological or infectious toxic effects. Similar to the compliance of treatment monitored in the second part of our trial, 79% patients completed the protocol therapy. Anyway, a comparison may not be possible given the preliminary data, the low number of patients, and the difference of population studied (88% of American Joint Committee on Cancer stage III in our study versus 39% in ECOG 3205). Patients in ECOG 3205 also usually received a lower dose of RT (45-54 Gy) than in the present study (65 Gy).
The schedule employed in ACCORD 16 was based on the results of the only one phase I trial reported. There, patients treated with CRT (55 Gy, 5-FU 1000 mg/m 2 /day and cisplatin 80 mg/m 2 /day) and cetuximab (400 mg/m 2 on day 1, then seven weekly doses of 250 mg/m 2 ) did not experience a dose-limiting toxicity [14] . However, no data on the use of G-CSF, dose constraints, and technique of RT employed in ECOG 3205 or the phase I reported by Olivatto et al. [14] were provided. In our trial, 11 out of 16 patients were treated with IMRT and 2 patients received a brachytherapy boost. It is well described that early and late local toxic effects in anal cancer correlate with the clinical stage and the type of technique of RT (including boost) [17] . IMRT appears to be effective and better tolerated than EBRT in the CRT regimen for the treatment of anal canal cancer [18] [19] [20] . In a series of 53 patients treated with CRT, including IMRT, Salama et al. [19] observed 15% digestive, 38% dermatological, and 34% neutropenia acute G3/4 toxicity, resulting in treatment breaks in ∼40% of patients. However, most of these patients underwent a 5-FU/mitomycin-C-based chemotherapy [18] [19] [20] . Although it is matter of debate [21] , recent randomized trials confirmed that definitive CRT with concurrent 5FU/mitomycin-C remains the standard of care, compared with 5-FU cisplatin, because it has a statistically significant, clinically meaningful impact on survival with similar toxic effects [22, 23] . Nevertheless, as in the ACCORD 03 trial [6] , cetuximab was associated with 5-FU/cisplatin in our analysis. In fact, at the time of the initiation of the study, early uncontrolled French collaborative studies suggested encouraging clinical results with the substitution of cisplatin for mitomycin-C [24] .
New early clinical trials, integrating IMRT and evaluating the feasibility of concurrent 5FU/mitomycin-C-based CRT with a range of anti-EGFR therapies (cetuximab: NCT01621217, panitumumab: NCT01285778/NCT01581840, or nimotuzumab: NCT01382745), are in progress. Still, results of ongoing phase II (ECOG 3205 and AMC045) are awaited to Annals of Oncology original articles
